(Q45168079)

English

Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Hiroaki Nagamatsu

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Satoshi Itano

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sakae Nagaoka

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Junji Akiyoshi

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Satoru Matsugaki

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Junichi Kurogi

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Nobuyoshi Tajiri

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sanki Yamasaki

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Hironori Koga

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Takuji Torimura

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Ryukichi Kumashiro

11

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Michio Sata

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

2369-2375

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40069.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2004.40069.X

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45168079&oldid=2068820241"